Monday, February 25, 2019
Mobidiag Ltd., a molecular diagnostic company currently in the development phase to tackle the spread of antimicrobial resistance, today announces the signing of several exclusive agreements with international partners to distribution of its Amplidiag ® and Novodiag ® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag ® and Novodiag ® with Helix2 for Greece and Interlab INTERAUTOMATIKA UAB for Latvia and Lithuania. Mobidiag also signed its first agreement in the Middle East with Ibn Rushd Medical & Scientific Equipment Co. for the distribution of Novodiag ® in Kuwait. The agreements are effective immediately and are planned for a period of two years.
Tuomas Tenkanen, CEO of Mobidiag, said, "We are delighted to have expanded our commercial presence into new international territories, including our first Middle East agreement. Mobidiag continues to see growing demand for Amplidiag ® and Novodiag ® solutions and we are in discussions with several other distribution partners in various international markets as customers seek comprehensive diagnostic solutions for a wide range of infectious diseases in centralized labs and decentralized. "
